Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report.
Acromegaly
Case report
Growth-hormone-secreting pituitary adenoma
Pituitary tumors
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
29 Apr 2021
29 Apr 2021
Historique:
received:
26
01
2021
accepted:
16
03
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
15
5
2021
Statut:
epublish
Résumé
Adjuvant endocrine therapy is recommended for the treatment of hormone-receptor-positive breast cancer. Aromatase inhibitors are associated with significant musculoskeletal adverse effects, likely through growth hormone/insulin-like growth factor 1 modulation, while tamoxifen reduces insulin-like growth factor 1 production. We describe the case of a patient who was treated successfully with tamoxifen for her hormone-receptor-positive breast cancer and acromegaly. A 57-year old White female with hormone-receptor-positive breast cancer was diagnosed with acromegaly. She received adjuvant endocrine therapy with anastrozole but could not tolerate this medication because of severe arthralgia, so she was switched to tamoxifen. Shortly after starting tamoxifen, the patient's musculoskeletal symptoms resolved and her insulin-like growth factor 1 levels normalized. She has remained in remission of her acromegaly and breast cancer since initiating tamoxifen. This case highlights the dual benefit of tamoxifen therapy in the treatment of hormone-receptor-positive breast cancer and acromegaly. Unlike anastrozole, tamoxifen has the benefit of lowering insulin-like growth factor 1 levels, which underscores its advantage in reducing adverse musculoskeletal symptoms during the treatment of hormone-receptor-positive breast cancer. We offer the first reported use of tamoxifen monotherapy for the successful treatment of acromegaly and hormone-receptor-positive breast cancer. While tamoxifen may offer an additional, oral option for acromegaly patients who do not respond to or tolerate conventional growth-hormone-lowering therapy, additional studies are necessary.
Sections du résumé
BACKGROUND
BACKGROUND
Adjuvant endocrine therapy is recommended for the treatment of hormone-receptor-positive breast cancer. Aromatase inhibitors are associated with significant musculoskeletal adverse effects, likely through growth hormone/insulin-like growth factor 1 modulation, while tamoxifen reduces insulin-like growth factor 1 production. We describe the case of a patient who was treated successfully with tamoxifen for her hormone-receptor-positive breast cancer and acromegaly.
CASE PRESENTATION
METHODS
A 57-year old White female with hormone-receptor-positive breast cancer was diagnosed with acromegaly. She received adjuvant endocrine therapy with anastrozole but could not tolerate this medication because of severe arthralgia, so she was switched to tamoxifen. Shortly after starting tamoxifen, the patient's musculoskeletal symptoms resolved and her insulin-like growth factor 1 levels normalized. She has remained in remission of her acromegaly and breast cancer since initiating tamoxifen.
CONCLUSION
CONCLUSIONS
This case highlights the dual benefit of tamoxifen therapy in the treatment of hormone-receptor-positive breast cancer and acromegaly. Unlike anastrozole, tamoxifen has the benefit of lowering insulin-like growth factor 1 levels, which underscores its advantage in reducing adverse musculoskeletal symptoms during the treatment of hormone-receptor-positive breast cancer. We offer the first reported use of tamoxifen monotherapy for the successful treatment of acromegaly and hormone-receptor-positive breast cancer. While tamoxifen may offer an additional, oral option for acromegaly patients who do not respond to or tolerate conventional growth-hormone-lowering therapy, additional studies are necessary.
Identifiants
pubmed: 33910628
doi: 10.1186/s13256-021-02792-8
pii: 10.1186/s13256-021-02792-8
pmc: PMC8082960
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Aromatase Inhibitors
0
Nitriles
0
Tamoxifen
094ZI81Y45
Anastrozole
2Z07MYW1AZ
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
207Références
Eur J Cancer. 2014 Nov;50(17):2925-31
pubmed: 25304297
J Clin Oncol. 2013 Aug 10;31(23):e398-400
pubmed: 23796991
Ann Oncol. 2013 Jun;24(6):1443-9
pubmed: 23471104
Pituitary. 2014 Dec;17(6):500-4
pubmed: 24243064
J Endocrinol Invest. 1997 Sep;20(8):445-51
pubmed: 9364247
Clin Endocrinol (Oxf). 1987 Apr;26(4):481-512
pubmed: 3308190
Breast. 2013 Dec;22(6):1155-60
pubmed: 23968866
J Clin Oncol. 2019 Feb 10;37(5):423-438
pubmed: 30452337
J Clin Endocrinol Metab. 2015 May;100(5):1863-9
pubmed: 25738590
Clin Breast Cancer. 2007 Oct;7(10):775-8
pubmed: 18021478
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1016-21
pubmed: 12552091
N Engl J Med. 2003 Feb 13;348(7):618-29
pubmed: 12584371
J Clin Endocrinol Metab. 1991 Feb;72(2):374-81
pubmed: 1991807
Lancet Oncol. 2010 Jun;11(6):530-42
pubmed: 20472501
Front Endocrinol (Lausanne). 2015 Apr 24;6:59
pubmed: 25964777
J Mol Endocrinol. 2018 Jul;61(1):T61-T68
pubmed: 29378771
Endocr Rev. 2009 Feb;30(1):51-74
pubmed: 19075184
J Clin Endocrinol Metab. 1998 Aug;83(8):2730-4
pubmed: 9709939
Pituitary. 2012 Dec;15 Suppl 1:S23-7
pubmed: 21221819
Cancer Res. 1989 Apr 1;49(7):1882-4
pubmed: 2924327